Tonix Pharmaceuticals Holding Corp. Company Profile (NASDAQ:TNXP)

About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. logoTonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TNXP
  • CUSIP: N/A
  • Web: www.tonixpharma.com
Capitalization:
  • Market Cap: $30.93 million
  • Outstanding Shares: 7,508,000
Average Prices:
  • 50 Day Moving Avg: $4.31
  • 200 Day Moving Avg: $4.12
  • 52 Week Range: $0.33 - $9.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.77
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.53 per share
  • Price / Book: 0.90
Profitability:
  • EBITDA: ($24,360,000.00)
  • Return on Equity: -84.89%
  • Return on Assets: -78.71%
Debt:
  • Current Ratio: 19.39%
  • Quick Ratio: 19.39%
Misc:
  • Average Volume: 113,165 shs.
  • Beta: 2.93
  • Short Ratio: 7.49
 

Frequently Asked Questions for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?

Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals Holding Corp.'s earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.65) EPS for the quarter, beating the Zacks' consensus estimate of ($0.78) by $0.13. View Tonix Pharmaceuticals Holding Corp.'s Earnings History.

When will Tonix Pharmaceuticals Holding Corp. make its next earnings announcement?

Tonix Pharmaceuticals Holding Corp. is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Tonix Pharmaceuticals Holding Corp..

Where is Tonix Pharmaceuticals Holding Corp.'s stock going? Where will Tonix Pharmaceuticals Holding Corp.'s stock price be in 2017?

5 brokerages have issued twelve-month target prices for Tonix Pharmaceuticals Holding Corp.'s shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Tonix Pharmaceuticals Holding Corp.'s stock price to reach $8.33 in the next year. View Analyst Ratings for Tonix Pharmaceuticals Holding Corp..

Who are some of Tonix Pharmaceuticals Holding Corp.'s key competitors?

How do I buy Tonix Pharmaceuticals Holding Corp. stock?

Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals Holding Corp.'s stock price today?

One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $4.08.


MarketBeat Community Rating for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals Holding Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $8.33 (104.25% upside)
Consensus Price Target History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Price Target History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/23/2017Dawson JamesReiterated RatingBuy$9.00MediumView Rating Details
8/22/2017Drexel HamiltonInitiated CoverageBuyHighView Rating Details
8/18/2017Roth CapitalUpgradeNeutral -> Buy$6.00HighView Rating Details
6/26/2017AegisInitiated CoverageBuy$10.00HighView Rating Details
12/20/2016Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings History by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.69)N/AView Earnings Details
8/14/2017Q2 2017($0.78)($0.65)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
2017 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.83)($0.83)($0.83)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.65)($0.65)($0.65)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 27.97%
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Institutional Ownership by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2017Seth LedermanCEOBuy20,000$3.00$60,000.00View SEC Filing  
6/30/2017Ernest MarioDirectorSell6,105$4.28$26,129.40View SEC Filing  
6/30/2017Seth LedermanCEOBuy5,000$4.33$21,650.00View SEC Filing  
6/26/2017Seth LedermanCEOBuy5,000$4.40$22,000.00View SEC Filing  
6/20/2017Seth LedermanCEOBuy20,000$4.22$84,400.00View SEC Filing  
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.00View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.00View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.00View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.00View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.00View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.30View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.00View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Source:
Loading headlines, please wait.

Social

Chart

Tonix Pharmaceuticals Holding Corp. (TNXP) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.